J.B. Chemicals & Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have each filed separate disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the stock exchanges of a Notice of Hearing of Petition in connection with the proposed Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited and their respective shareholders. Both disclosures were made on 11th May 2026 and were accompanied by newspaper advertisement cuttings published in Indian Express (English) — all India Editions and Sandesh, Divya Bhaskar & Gujarat Samachar (Gujarati) — all in Gujarat Editions on 11th May 2026.

Amalgamation Petition Before NCLT

A Company Petition under Sections 230 and 232 and other applicable provisions of the Companies Act, 2013 has been filed for sanctioning the Scheme of Arrangement in the nature of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited (Petitioner Transferor Company / JB Pharma) with Torrent Pharmaceuticals Limited (Petitioner Transferee Company / Torrent Pharma) and their respective shareholders. The key procedural milestones in the petition process are outlined below:

Details of the Petitioner Companies

The two companies involved in the proposed amalgamation are both incorporated under the Companies Act, 1956 and are registered in the State of Gujarat. Their details are as follows:

Participation and Representation Process

Any person seeking to support or oppose the Company Petition at the hearing is required to submit an affidavit with the grounds of support or opposition in the form of a representation before the Hon'ble Tribunal. Such persons must also provide a written copy to the Petitioner Companies' Advocate, Swati Soparkar, at 301, Shivalik-10, Opp. SBI Zonal Office, Near Old Excise Chowky, S.M. Road, Ambavadi, Ahmedabad – 380 015, and/or at swati.soparkar@gmail.com .

Copies must also be addressed to the respective Company Secretaries and Compliance Officers of both petitioner companies:

• JB Pharma: Mr. Sandeep Phadnis, Company Secretary & Compliance Officer, Neelam Centre, 'B' Wing, 4th floor, Hind Cycle Road, Worli, Mumbai 400030
• Torrent Pharma: Mr. Chintan Trivedi, Company Secretary & Compliance Officer, Avirat, Thaltej Shilaj Road, Ahmedabad – 380 059, Gujarat, India

All representations must be received no later than two days before the date fixed for the hearing of the Company Petition. Interested parties may appear in person or through their advocate. A copy of the Company Petition will be furnished to any person requiring the same on payment of the prescribed charges.

Regulatory Disclosure

The disclosure on behalf of Torrent Pharmaceuticals Limited was signed by Chintan M. Trivedi, Company Secretary, while the disclosure on behalf of J.B. Chemicals & Pharmaceuticals Limited was signed by Sandeep Phadnis, Vice President – Secretarial & Company Secretary. Both submissions were made to BSE Limited and the National Stock Exchange of India Ltd. on 11th May 2026, in compliance with applicable SEBI listing regulations.

Torrent Pharmaceuticals has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Friday, May 22, 2026, pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 9, 2026, and signed by Company Secretary Chintan M Trivedi.

Key Agenda Items for the Board Meeting

The Board meeting has been convened to address several significant matters. The following table outlines the key agenda items scheduled for deliberation:

Audited Financial Results for FY26

The primary agenda of the May 22, 2026 Board meeting is the consideration and approval of the audited financial results of the company for the year ended March 31, 2026. This is a mandatory disclosure requirement under applicable SEBI regulations, and the results, once approved, will be disseminated to the stock exchanges.

Dividend and Fund-Raising Plans

Alongside the financial results, the Board will consider the recommendation of a final dividend, if any, on the equity shares of the company for the year 2025-26. The Board will also take up enabling resolutions for raising funds through the following instruments:

• Issue of Equity Shares including Convertible Bonds/Debentures through Qualified Institutional Placement (QIP)
• Depository Receipts
• Any other permissible modes

If the Board approves the fund-raising resolution, the matter will subsequently be placed for shareholders' approval at the ensuing Annual General Meeting (AGM).

Regulatory Compliance

The intimation has been filed in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates prior notice to stock exchanges before Board meetings where financial results or dividend recommendations are to be considered. The notice was addressed to both BSE Limited and the National Stock Exchange of India Ltd.